Literature DB >> 9472750

Loss of spiral ganglion cells as primary manifestation of aminoglycoside ototoxicity.

M Sone1, P A Schachern, M M Paparella.   

Abstract

Although pulmonary infections caused by Pseudomonas aeruginosa can hardly be eradicated in patients with cystic fibrosis (CF, the most common genetic disease among Caucasians), these patients are mainly treated with intravenous and nebulized tobramycin. Long-term treatment with tobramycin, however, may induce ototoxic effects. We assessed the clinical histories and postmortem temporal bones of six patients with CF for signs of this ototoxicity. Four bones showed typical manifestations of ototoxicity induced by aminoglycosides (AGs): loss of hair cells in the lower turns, and degeneration of ganglion cells. Six bones revealed no loss or scattered loss of hair cells, however, degeneration of the spiral ganglion cells was observed. This suggests that degeneration of the spiral ganglion may occur as a primary manifestation in some cases of ototoxicity due to aminoglycosides. Recent reports have shown that trophic factors (neurotrophins and acidic fibroblast growth factor) interacting with hair cells and the spiral ganglion protect the inner ear from damage. It may be that disturbances in supply of such trophic factors caused degeneration of ganglion cells without loss of hair cells in the cases we studied.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9472750     DOI: 10.1016/s0378-5955(97)00191-3

Source DB:  PubMed          Journal:  Hear Res        ISSN: 0378-5955            Impact factor:   3.208


  15 in total

Review 1.  Cochlear synaptopathy in acquired sensorineural hearing loss: Manifestations and mechanisms.

Authors:  M Charles Liberman; Sharon G Kujawa
Journal:  Hear Res       Date:  2017-01-10       Impact factor: 3.208

2.  Spatial selectivity to intracochlear electrical stimulation in the inferior colliculus is degraded after long-term deafness in cats.

Authors:  Maike Vollmer; Ralph E Beitel; Russell L Snyder; Patricia A Leake
Journal:  J Neurophysiol       Date:  2007-09-12       Impact factor: 2.714

Review 3.  Delivery of therapeutics to the inner ear: The challenge of the blood-labyrinth barrier.

Authors:  Sophie Nyberg; N Joan Abbott; Xiaorui Shi; Peter S Steyger; Alain Dabdoub
Journal:  Sci Transl Med       Date:  2019-03-06       Impact factor: 17.956

4.  Changes in the inner ear structures in cystic fibrosis patients.

Authors:  Henrique F Pauna; Rafael C Monsanto; Natsuko Kurata; Michael M Paparella; Sebahattin Cureoglu
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2016-11-16       Impact factor: 1.675

Review 5.  Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis.

Authors:  N Høiby
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

6.  Gentamicin concentration gradients in scala tympani perilymph following systemic applications.

Authors:  Hartmut Hahn; Alec N Salt; Ulrike Schumacher; Stefan K Plontke
Journal:  Audiol Neurootol       Date:  2013-11-01       Impact factor: 1.854

Review 7.  Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention.

Authors:  Jochen Schacht; Andra E Talaska; Leonard P Rybak
Journal:  Anat Rec (Hoboken)       Date:  2012-10-08       Impact factor: 2.064

8.  Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in a Pediatric Cystic Fibrosis Cohort.

Authors:  Chelsea M Blankenship; Lisa L Hunter; M Patrick Feeney; Madison Cox; Lindsey Bittinger; Angela C Garinis; Li Lin; Gary McPhail; John P Clancy
Journal:  Am J Audiol       Date:  2021-01-19       Impact factor: 1.636

9.  Peripheral Auditory Involvement in Childhood Listening Difficulty.

Authors:  Lisa L Hunter; Chelsea M Blankenship; Li Lin; Nicholette T Sloat; Audrey Perdew; Hannah Stewart; David R Moore
Journal:  Ear Hear       Date:  2021 Jan/Feb       Impact factor: 3.562

Review 10.  Age-related hearing impairment and the triad of acquired hearing loss.

Authors:  Chao-Hui Yang; Thomas Schrepfer; Jochen Schacht
Journal:  Front Cell Neurosci       Date:  2015-07-27       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.